{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:20:45Z","timestamp":1755800445940,"version":"3.44.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,20]]},"DOI":"10.7759\/cureus.90563","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T10:45:37Z","timestamp":1755686737000},"source":"Crossref","is-referenced-by-count":0,"title":["Lymphoblastic Leukemia With P2RY8::CRLF2 Rearrangement and High Hyperdiploidy"],"prefix":"10.7759","author":[{"given":"Yui","family":"Tsunoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukushima","family":"Hiroko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Nanmoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter V","year":"2010","unstructured":"Conter V, Bartram CR, Valsecchi MG, et al.. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010, 115:3206-14. 10.1182\/blood-2009-10-248146","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322909","article-title":"Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"118","author":"Matloub Y","year":"2011","unstructured":"Matloub Y, Bostrom BC, Hunger SP, et al.. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011, 118:243-51. 10.1182\/blood-2010-12-322909","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood Oncology Group","volume":"34","author":"Pieters R","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V, et al.. Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch childhood Oncology Group. J Clin Oncol. 2016, 34:2591-601. 10.1200\/JCO.2015.64.6364","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-743252","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"130","author":"Tasian SK","year":"2017","unstructured":"Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017, 130:2064-72. 10.1182\/blood-2017-06-743252","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758979","article-title":"Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group","volume":"129","author":"Reshmi SC","year":"2017","unstructured":"Reshmi SC, Harvey RC, Roberts KG, et al.. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017, 129:3352-61. 10.1182\/blood-2016-12-758979","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000163","article-title":"Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"4","author":"Harvey RC","year":"2020","unstructured":"Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv. 2020, 4:218-28. 10.1182\/bloodadvances.2019000163","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.365","article-title":"Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia","volume":"31","author":"Vesely C","year":"2017","unstructured":"Vesely C, Frech C, Eckert C, et al.. Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia. Leukemia. 2017, 31:1491-501. 10.1038\/leu.2016.365","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.101","article-title":"Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia","volume":"26","author":"Palmi C","year":"2012","unstructured":"Palmi C, Vendramini E, Silvestri D, et al.. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. Leukemia. 2012, 26:2245-53. 10.1038\/leu.2012.101","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1128","article-title":"Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia","volume":"102","author":"Moorman AV","year":"2003","unstructured":"Moorman AV, Richards SM, Martineau M, et al.. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia. Blood. 2003, 102:2756-62. 10.1182\/blood-2003-04-1128","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.06980.x","article-title":"Outcome of ETV6\/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival","volume":"140","author":"Forestier E","year":"2008","unstructured":"Forestier E, Heyman M, Andersen MK, et al.. Outcome of ETV6\/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival. Br J Haematol. 2008, 140:665-72. 10.1111\/j.1365-2141.2008.06980.x","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12836","article-title":"Prognostic impact of gained chromosomes in high-hyperdiploid childhood acute lymphoblastic leukaemia: a collaborative retrospective study of the Tokyo Children's Cancer Study Group and Japan Association of Childhood Leukaemia Study","volume":"166","author":"Kato M","year":"2014","unstructured":"Kato M, Imamura T, Manabe A, et al.. Prognostic impact of gained chromosomes in high-hyperdiploid childhood acute lymphoblastic leukaemia: a collaborative retrospective study of the Tokyo Children's Cancer Study Group and Japan Association of Childhood Leukaemia Study. Br J Haematol. 2014, 166:295-8. 10.1111\/bjh.12836","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V79.12.3316.bloodjournal79123316","article-title":"Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study","volume":"79","author":"Harris MB","year":"1992","unstructured":"Harris MB, Shuster JJ, Carroll A, et al.. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992, 79:3316-24.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts KG","year":"2014","unstructured":"Roberts KG, Pei D, Campana D, et al.. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014, 32:3012-20. 10.1200\/JCO.2014.55.4105","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.085852","article-title":"High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992\/2000 protocols","volume":"98","author":"Paulsson K","year":"2013","unstructured":"Paulsson K, Forestier E, Andersen MK, et al.. High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992\/2000 protocols. Haematologica. 2013, 98:1424-32. 10.3324\/haematol.2013.085852","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1064555","article-title":"High hyperdiploid childhood acute lymphoblastic leukemia: chromosomal gains as the main driver event","volume":"3","author":"Paulsson K","year":"2016","unstructured":"Paulsson K. High hyperdiploid childhood acute lymphoblastic leukemia: chromosomal gains as the main driver event. Mol Cell Oncol. 2016, 3:e1064555. 10.1080\/23723556.2015.1064555","journal-title":"Mol Cell Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00811","article-title":"JCCG all-B12: evaluation of intensified therapies with vincristine\/dexamethasone pulses and asparaginase and augmented high-dose methotrexate for pediatric B-ALL","volume":"43","author":"Kato M","year":"2025","unstructured":"Kato M, Okamoto Y, Imamura T, et al.. JCCG all-B12: evaluation of intensified therapies with vincristine\/dexamethasone pulses and asparaginase and augmented high-dose methotrexate for pediatric B-ALL. J Clin Oncol. 2025, 43:567-77. 10.1200\/JCO.24.00811","journal-title":"J Clin Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui CH","year":"2008","unstructured":"Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008, 371:1030-43. 10.1016\/S0140-6736(08)60457-2","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-297135","article-title":"Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial","volume":"117","author":"Ensor HM","year":"2011","unstructured":"Ensor HM, Schwab C, Russell LJ, et al.. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood. 2011, 117:2129-36. 10.1182\/blood-2010-07-297135","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger SP","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015, 373:1541-52. 10.1056\/NEJMra1400972","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388368-lymphoblastic-leukemia-with-p2ry8crlf2-rearrangement-and-high-hyperdiploidy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T10:45:38Z","timestamp":1755686738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388368-lymphoblastic-leukemia-with-p2ry8crlf2-rearrangement-and-high-hyperdiploidy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.90563","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}